Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial

BACKGROUND: Empagliflozin slowed the progression of CKD in patients with type 2 diabetes and cardiovascular disease in the EMPA-REG OUTCOME Trial. In a prespecified statistical approach, we assessed treatment differences in kidney function by analyzing slopes of eGFR changes. METHODS: Participants (...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Am Soc Nephrol
Prif Awduron: Wanner, Christoph, Heerspink, Hiddo J.L., Zinman, Bernard, Inzucchi, Silvio E., Koitka-Weber, Audrey, Mattheus, Michaela, Hantel, Stefan, Woerle, Hans-Juergen, Broedl, Uli C., von Eynatten, Maximilian, Groop, Per-Henrik
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society of Nephrology 2018
Pynciau:
Clinical Research
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6218863/
https://ncbi.nlm.nih.gov/pubmed/30314978
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1681/ASN.2018010103
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg